Infect Chemother.  2014 Sep;46(3):194-198. 10.3947/ic.2014.46.3.194.

Physician Attitudes toward the Herpes Zoster Vaccination in South Korea

• Yang TU
• Cheong HJ
• Choi WS
• Song JY
• Noh JY
• Kim WJ

• KMID: 2284977
• DOI: http://doi.org/10.3947/ic.2014.46.3.194

Abstract

This survey investigated Korean physician attitudes toward the herpes zoster (HZ) vaccine. A total of 400 physicians answered a self-reported questionnaire. Most physicians knew that HZ poses a significant socioeconomic burden and had good knowledge about HZ and its vaccine. Physicians who did not recommend HZ vaccine were concerned about costs (90.7%, 78/86) and doubted the effectiveness of the vaccine (58.1%, 50/86). Patient demand had a profound effect on physicians decisions; 84.9% (73/86) of them who said not recommending HZ vaccine reported that they would provide the vaccine upon patient request. In conclusion, educational initiatives should be targeted toward both physicians and patients.

Keyword

Herpes zoster; Physician; Vaccination; Awareness; Health surveys

MeSH Terms

Health Surveys
Herpes Zoster*
Humans
Korea
Vaccination*
Surveys and Questionnaires

Reference

1. Song H, Lee J, Lee M, Choi WS, Choi JH, Lee MS, Hashemi M, Rampakakis E, Kawai K, White R, Acosta C, Sampalis JS, Cheong HJ. Burden of illness, quality of life, and healthcare utilization among patients with herpes zoster in South Korea: a prospective clinical-epidemiological study. Int J Infect Dis. 2014; 20:23–30.

2. Wareham DW, Breuer J. Herpes zoster. BMJ. 2007; 334:1211–1215.

3. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013; 10:e1001420.

4. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine. 2009; 27:882–887.

5. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352:2271–2284.

6. Joon Lee T, Hayes S, Cummings DM, Cao Q, Carpenter K, Heim L, Edwards H. Herpes zoster knowledge, prevalence, and vaccination rate by race. J Am Board Fam Med. 2013; 26:45–51.

7. Zimmerman RK, Santibanez TA, Janosky JE, Fine MJ, Raymund M, Wilson SA, Bardella IJ, Medsger AR, Nowalk MP. What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and Veterans Affairs practices. Am J Med. 2003; 114:31–38.

8. Seewald L, Hurley L, Crane LA, Dong F, Stokley S, Daley MF, Barrow J, Babbel C, Dickinson LM, Kempe A. Things are not as bad as they seem: physicians' ability to predict their clinical practice when a new vaccine becomes available. Healthc Policy. 2013; 8:71–85.

9. Centers for Disease Control (CDC). Adult immunization: knowledge, attitudes, and practices--DeKalb and Fulton Counties, Georgia, 1988. MMWR Morb Mortal Wkly Rep. 1988; 37:657–661.

10. Nichol KL, Mac Donald R, Hauge M. Factors associated with influenza and pneumococcal vaccination behavior among high-risk adults. J Gen Intern Med. 1996; 11:673–677.

11. Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, Dong F, Beaty BL, Tan L, Babbel C, Dickinson LM, Kempe A. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010; 152:555–560.

12. Elkin Z, Cohen EJ, Goldberg JD, Gillespie C, Li X, Jung J, Cohen M, Park L, Perskin MH. Studying physician knowledge, attitudes, and practices regarding the herpes zoster vaccine to address perceived barriers to vaccination. Cornea. 2013; 32:976–981.

13. Franco MF. Physicians' attitudes towards human papillomavirus vaccination programme: a systematic review [dissertation]. Chester, England: University of Chester;2011.

14. Wong MC, Lee A, Ngai KL, Chor JC, Chan PK. Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong. PLoS One. 2013; 8:e71827.

15. Choi WS. Herpes zoster vaccine in Korea. Clin Exp Vaccine Res. 2013; 2:92–96.

16. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012; 54:922–928.